Glycogene Discovery Service in Prostate Cancer

Glycogene Discovery Service in Prostate Cancer

Prostate Cancer and Glycosylation

Prostate cancer is a kind of cancer commonly found among men. A well-known hallmark of cancer is changes in protein glycosylation, which is related to the differential expression of enzymes. The changed expression of the enzymes promoted cancer cells to produce glycoproteins with specific cancer-related aberrations in glycan structures. Glycoproteins are often considered as prognostic biomarkers for monitoring tumor progression and predictive biomarkers for disease recurrence. Prostate-specific antigen is the biomarker that is used most frequently for prostate cancer detection. Extensive glycosylation changes in prostate cancer cells, including increased sialylation and fucosylation, can alter protein function and play key roles in many important biological processes in cancer, including cell signaling, adhesion, migration, and cellular metabolism.

Glycogene Discovery Service in Prostate Cancer

CD BioGlyco has an expert team with strong scientific research capabilities and an advanced technology platform. With constant collaboration and innovation, CD BioGlyco provides Cancer Glycogene Discovery Services to support cancer glycogene research. We provide some glycan biomarkers and their detection methods for prostate cancer.

  • Discovery methods
    • Mass spectrometry (MS), matrix-assisted laser desorption/ionization (MALDI-MS), liquid chromatography (LC), etc.
      To identify glycoprotein structure.
    • LC-MS/MS
      To identify and quantify glycopeptides.
    • The quantitative real-time polymerase chain reaction (qRT-PCR) and RNA sequencing (RNA-Seq)
      To assess genes and their splicing variants in tumor tissues.
    • Glycoproteogenomics
      To identify multiple glycoprotein forms.
    • Systematic transcriptomic analysis
      To identify the gene signature for glycogene-type classification.
  • Summary of glycogenes involved in prostate cancer
    • Prostate-specific antigen (PSA)
    • prostate cancer gene 3 (PCA3)
    • Prostate-specific membrane antigen (PSMA)
    • Alpha-methylacyl-CoA racemase (AMACR)
    • Prostatic acid phosphatase (PAP)
    • Annexin A3 (ANXA3)
    • PENTRAXIN-3 (PTX-3)
    • GALNT7 (a glycosyltransferase)

Fig.1 Glycogene discovery service in prostate cancer. (CD BioGlyco)Fig.1 Glycogene discovery service in prostate cancer. (CD BioGlyco)


  • Aberrant protein glycosylation has potential applications in non-invasive diagnostic procedures for prostate diseases.
  • Cancer-related glycoforms and glycosyltransferases related to the synthesis of such glycans may be used for drug discovery.
  • Widely used in recurrence assessment and metastasis risk research of prostate cancer patients.
  • Our service enhances the understanding of aberrant glycosylation and carcinogenesis and accelerates biomarker recognition and quantitative detection.


  • Professional research teams and advanced technical means.
  • Fully custom-designed one-stop service.
  • Professional advice from our analysis scientists.
  • Combination of multiple advanced analysis platforms.

CD BioGlyco has enriched the Glycogenomics Platform to cover our customer's essential needs. In addition, our expert team has extensive experience in Glycogene Editing and Glycogene Delivery. Welcome to feel free to contact us for custom service. We look forward to your happy cooperation.


  1. Kałuża, A.; et al. Glycosylation: rising potential for prostate cancer evaluation. Cancers (Basel). 2021, 13(15): 3726.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.